Core Viewpoint - Catalyst Pharmaceuticals, Inc. is set to release its third quarter 2024 financial results on November 6, 2024, followed by a conference call on November 7, 2024, to discuss these results and provide a business update [1]. Company Overview - Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a commitment to improving patient lives [2]. - The company has a proven track record of bringing innovative therapies to market and emphasizes accessibility through comprehensive support services [2]. - Catalyst is headquartered in Coral Gables, Florida, and has been recognized as one of America's most successful small-cap companies by Forbes in 2024 [2].

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Core Points - Catalyst Pharmaceuticals, Inc. has donated $100,000 to the American Red Cross to support relief efforts for communities affected by Hurricane Helene [1][2] - The company emphasizes its commitment to the community, particularly during crises, and aims to help ensure essential resources reach those in need [2] - The American Red Cross has mobilized over 1,400 disaster responders across the Carolinas, Tennessee, Georgia, and Florida to provide shelter, meals, and comfort to families impacted by the hurricane [2] Company Overview - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing therapies for rare diseases [4] - The company has a proven track record of bringing life-changing treatments to market and prioritizes patient care and accessibility [4] - Catalyst is headquartered in Coral Gables, FL, and has been recognized as one of America's most successful small-cap companies by Forbes in 2024 [4]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Catalyst Pharmaceuticals (CPRX) : This commercial-stage biopharmaceutical company which is focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.7% over the last 60 days. HCI Group (HCI) : This company which is engaged in diverse business activities, including property and casualty insurance, informat ...

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings e ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...

Catalyst Pharmaceutical (CPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a ...

CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE® (amif ...

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 14.1 million (H1-2023: CHF 3.9 million) Operating result of CHF -17.7 million (H1-2023: CHF -20.3 million) and net result of CHF -15.3 million (H1-2023: CHF -23.3 million) AGAMREE® (vamorolone) launched in Germany and Austria as first European markets; North America partner has launche ...

Core Insights - Catalyst Pharmaceutical reported adjusted earnings of 56 cents per share for Q2 2024, exceeding the Zacks Consensus Estimate of 42 cents and showing growth from 53 cents in the same quarter last year [2] - Total revenues reached $122.7 million, a 23% year-over-year increase, surpassing the Zacks Consensus Estimate of $111.6 million [2] Revenue Breakdown - Firdapse sales amounted to $77.4 million, reflecting a 19.2% year-over-year growth and beating the Zacks Consensus Estimate of $72.5 million [3] - Fycompa generated net product revenues of $36.5 million, exceeding the Zacks Consensus Estimate of $33.2 million and showing a year-over-year growth of 5.7% [5] - Agamree, launched in March 2024, generated revenues of $8.7 million in its first full quarter, surpassing the Zacks Consensus Estimate of $6 million [7] Expense Overview - Research and development (R&D) expenses were $3 million, down 25% year-over-year [7] - Selling, general and administrative (SG&A) expenses totaled $40.7 million, up 43% from $28.4 million in the previous year, primarily due to the launch of Agamree [8] Financial Guidance - Catalyst expects total revenues for 2024 to be between $455 million and $475 million, with Firdapse revenues projected at $295 million to $310 million and Fycompa revenues between $130 million and $135 million [9][10] - The revenue guidance for Agamree has been increased to $35 million to $40 million from the previous range of $25 million to $30 million [10] Market Performance - Catalyst shares have increased by approximately 8.3% since the last earnings report, outperforming the S&P 500 [1] - The consensus estimate for Catalyst has shifted upward by 5.14% in the past month, indicating positive investor sentiment [11] Industry Context - Catalyst operates within the Zacks Medical - Drugs industry, where Corcept Therapeutics reported revenues of $163.8 million, a year-over-year increase of 39.1% [14]